| 10.5 0.43 (4.27%) | 12-31 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 13.2 | 1-year : | 14.49 |
| Resists | First : | 11.3 | Second : | 12.4 |
| Pivot price | 10.12 |
|||
| Supports | First : | 9.52 | Second : | 7.92 |
| MAs | MA(5) : | 10.25 |
MA(20) : | 10.22 |
| MA(100) : | 8.67 |
MA(250) : | 0 | |
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 70.3 |
D(3) : | 56.7 |
| RSI | RSI(14): 54.6 |
|||
| 52-week | High : | 12.4 | Low : | 3.29 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ IMTX ] has closed below upper band by 5.8%. Bollinger Bands are 59.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 10.52 - 10.59 | 10.59 - 10.65 |
| Low: | 9.86 - 9.93 | 9.93 - 10 |
| Close: | 10.38 - 10.5 | 10.5 - 10.6 |
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
Wed, 31 Dec 2025
Immatics (NASDAQ:IMTX) Trading Up 3.9% - Time to Buy? - MarketBeat
Sat, 27 Dec 2025
(IMTX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Thu, 25 Dec 2025
Immatics: PRAME Leader's Transition To Commercial Reality - Seeking Alpha
Sat, 20 Dec 2025
Mizuho Securities Sticks to Their Buy Rating for Immatics (IMTX) - The Globe and Mail
Wed, 17 Dec 2025
How Immatics’ US$125 Million Follow-on Equity Raise At Immatics (IMTX) Has Changed Its Investment Story - Sahm
Fri, 05 Dec 2025
Revenues Not Telling The Story For Immatics N.V. (NASDAQ:IMTX) After Shares Rise 28% - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 134 (M) |
| Held by Insiders | 5.002e+007 (%) |
| Held by Institutions | 22.8 (%) |
| Shares Short | 5,860 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.3342e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -141.6 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 53.2 % |
| Return on Equity (ttm) | -16.3 % |
| Qtrly Rev. Growth | 8.476e+007 % |
| Gross Profit (p.s.) | -65.96 |
| Sales Per Share | -22.09 |
| EBITDA (p.s.) | -6.71176e+007 |
| Qtrly Earnings Growth | -1.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -176 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.48 |
| Price to Cash Flow | 3.55 |
| Dividend | 0 |
| Forward Dividend | 5.58e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|